肺癌筛查中联合支气管舒张前肺功能检查的诊断与治疗结局
在 Yorkshire 肺癌筛查试验的 Lung Health Check 中,2391 名参与者接受支气管舒张前肺功能检查,201 人(8.4%)符合转诊标准,最终 59 人获得新 COPD 编码、56 人启用新药物治疗。研究提示筛查中肺功能可促进 COPD 早期诊断,但强调诊断治疗前需用支气管舒张后肺功能确认气流阻塞。
要点
- 肺癌筛查中联合肺功能可发现未诊断 COPD,201/2391(8.4%)符合转诊标准。
- 70 人复查支气管舒张后肺功能,20 人(29%)无气流阻塞,提示需确认诊断。
- 最终 59 人获新 COPD 编码、56 人启用新药、5 人接受肺康复。
核心结论
- 在肺癌筛查中联合肺功能检查可能促进 COPD 的早期诊断。
- 诊断和治疗 COPD 前需通过支气管舒张后肺功能确认气流阻塞。
- 对筛查中收集的肺功能结果采取行动存在下游挑战。
研究设计与样本
- 研究嵌套于 Yorkshire 肺癌筛查试验的 Lung Health Check 项目。
- 参与者同时接受低剂量 CT 筛查和支气管舒张前肺功能检查。
- 共 2391 名参与者接受支气管舒张前肺功能检查。
- 结果告知全科医生,符合标准的不明原因症状性气流阻塞者转诊至 Leeds 社区呼吸团队。
- 回顾基层医疗记录以确定诊断编码和药物治疗变化。
主要发现
- 201 名(8.4%)参与者符合社区呼吸团队转诊标准,其中 151 人被邀请进一步评估。
- 70 人复查支气管舒张后肺功能,其中 20 人(29%)无气流阻塞。
- 在转诊至社区呼吸团队且支气管舒张后确认气流阻塞者中,59 人获得新 COPD 编码、56 人启用新药物治疗、5 人接受肺康复。
- 上述分别占 2391 名参与者的 2.5%、2.3% 和 0.2%。
临床怎么用
- 肺癌筛查中可同步进行肺功能检查以发现未诊断的 COPD。
- 对筛查中发现的气流阻塞,应复查支气管舒张后肺功能确认后再诊断和治疗。
- 需建立筛查结果向基层医疗和专科转诊的有效衔接流程。
局限性
- 部分转诊患者拒绝评估或已在全科医生处就诊,可能影响结局评估。
- 仅 70 人复查支气管舒张后肺功能,确认气流阻塞的比例基于有限样本。
- 研究未详细描述下游影响的其他方面。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Incorporating spirometry into low-dose CT (LDCT) screening for lung cancer may help identify people with undiagnosed chronic obstructive pulmonary disease (COPD), although the downstream impacts are not well described. METHODS: Participants attending a Lung Health Check (LHC) as part of the Yorkshire Lung Screening Trial were offered spirometry alongside LDCT screening. Results were communicated to the general practitioner (GP), and those with unexplained symptomatic airflow obstruction (AO) fulfilling agreed criteria were referred to the Leeds Community Respiratory Team (CRT) for assessment and treatment. Primary care records were reviewed to determine changes to diagnostic coding and pharmacotherapy. RESULTS: Of 2391 LHC participants undergoing prebronchodilator spirometry, 201 (8.4%) fulfilled the CRT referral criteria of which 151 were invited for further assessment. Ninety seven participants were subsequently reviewed by the CRT, 46 declined assessment and 8 had already been seen by their GP at the time of CRT contact. Overall 70 participants had postbronchodilator spirometry checked, of whom 20 (29%) did not have AO. Considering the whole cohort referred to the CRT (but excluding those without AO postbronchodilation), 59 had a new GP COPD code, 56 commenced new pharmacotherapy and 5 were underwent pulmonary rehabilitation (comprising 2.5%, 2.3% and 0.2% of the 2391 participants undergoing LHC spirometry). CONCLUSIONS: Delivering spirometry alongside lung cancer screening may facilitate earlier diagnosis of COPD. However, this study highlights the importance of confirming AO by postbronchodilator spirometry prior to diagnosing and treating patients with COPD and illustrates some downstream challenges in acting on spirometry collected during an LHC.
引用
- Bradley C, Boland A, Clarke L, et al. Diagnosis and treatment outcomes from prebronchodilator spirometry performed alongside lung cancer screening in a Lung Health Check programme. Thorax. 2023. PMID: 36972979. doi:10.1136/thorax-2022-219683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。